Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | EED | O75530 | 6/20 | 0.36 |
| ▸ | RBBP4 | Q09028 | 6/20 | 0.36 |
| ▸ | SUZ12 | Q15022 | 6/20 | 0.36 |
| ▸ | AEBP2 | Q6ZN18 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30785590 | 0.77 | EZH2 (0.37) | EZH2EHMT2EEDRBBP4SUZ12 | |
| SCHEMBL30148788 | 0.73 | EZH2 (0.39) | EZH2EHMT2EEDRBBP4SUZ12 | |
| SCHEMBL28744768 | 0.70 | EZH2 (0.63) | EZH2EHMT2EEDRBBP4SUZ12 | |
| SCHEMBL28523974 | 0.70 | CDK1 (0.57) | NPC1MAPT | |
| SCHEMBL30148823 | 0.69 | CTSL (0.45) | EZH2 | |
| SCHEMBL2917889 | 0.69 | KMT2A (0.36) | SMN1; SMN2 | |
| SCHEMBL31491388 | 0.68 | PDE10A (0.44) | NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30148806 | 0.67 | CDK1 (0.45) | EZH2 | |
| SCHEMBL31491313 | 0.67 | NPC1 (0.35) | NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30785579 | 0.66 | KDM4E (0.36) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4596554-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Suzhou Arkbiopharmaceutical Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | PDE4B, PDE4A, CYP4A11 | EZH2 916/4885EHMT2 1183/4885EED 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.